Implications for reproductive medicine sex differences in cardiovascular disease

Sexuality, Reproduction and Menopause

Volumn 9, Issue 3, 2011, Pages 21-28

  Miller, Virginia M ^a   Best, Patricia J M ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROGESTERONE; SEX HORMONE; TESTIS DETERMINING FACTOR; TESTOSTERONE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ERECTILE DYSFUNCTION; HEART INFARCTION; HEREDITY; HOT FLUSH; HUMAN; HYPERTENSION; LOW DRUG DOSE; NONHUMAN; OVARY POLYCYSTIC DISEASE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX CHROMOSOME; SEX DIFFERENCE; THROMBOCYTE; THROMBOSIS;

EID: 80052246893     PISSN: 15462501     EISSN: 18787576     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. References
2. Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7): e46-e215.
3. Simon VR, Hai T, Williams SK, et al. National Institutes of Health: intramural and extramural support for research on sex differences, 2000-2003. Scientific Report Series: Understanding the Biology of Sex Differences. Washington, DC: Society for Women's Health Research; 2005.
4. Mosca L, Benjamin EJ, Berra K, et al; American Heart Association. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-1262.
5. Wizemann TM, Pardue ML, eds; Board on Health Sciences Policy, Institute of Medicine. Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington, DC: National Academy Press; 2001.
6. Goldberg RJ, O'Donnell C, Yarzebski J, et al. Sex differences in symptom presentation associated with acute myocardial infarction: a population-based perspective. Am Heart J. 1998; 136(2): 189-195.
7. Berookhim BM, Bar-Chama N. Medical implications of erectile dysfunction. Med Clin North Am. 2011;95(1):213-221.
8. Garovic VD, Bailey KR, Boerwinkle E, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens. 2010;28(4):826-833.
9. Hart EC, Charkoudian N, Miller VM. Sex, hormones and neuroeffector mechanisms [published online ahead of print September 27, 2010]. Acta Physiol (Oxf). doi:10.1111/j.1748-1716.2010.02192.x.
10. Bairey Merz CN, Shaw LJ, Reis SE, et al; WISE Investigators. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study: Part II: gender differences in presentation, diagnosis, and outcome with regard to genderbased pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(3 suppl):S21-S29.
11. Miller VM. Sex-based differences in vascular funciton. Women's Health (London Engl). 2010;6(5):737-752.
12. Van PL, Bakalov VK, Zinn AR, Bondy CA. Maternal X chromosome, visceral adiposity, and lipid profile. JAMA. 2006;295(12):1373-1374.
13. Ely D, Milsted A, Bertram J, et al. Sry delivery to the adrenal medulla increases blood pressure and adrenal medullary tyrosine hydroxylase of normotensive WKY rats. BMC Cardiovasc Disord. 2007;7:6.
14. Arnold AP, Chen X. What does the "four core genotypes" mouse model tell us about sex differences in the brain and other tissues? Front Neuroendocrinol. 2009;30(1):1-9.
15. Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev. 2011;35(3):565-572.
16. Kim AM, Tingen CM, Woodruff TK. Sex bias in trials and treatment must end. Nature. 2010;465(729):688-689.
17. Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis and reporting of sex and race/ethnicity in clinical trials: have we made progress? J Women's Health (Larchmt). 2011;20(3):315-320.
18. Bauer A, Malik M, Schmidt G, et al. Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus. J Am Coll Cardiol 2008;52(17):1353-1365.
19. Croghan IT, Ebbert JO, Hurt RD, et al. Gender differences among smokers receiving interventions for tobacco dependence in a medical setting. Addict Behav. 2009;34(1):61-67.
20. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
21. Cannon CP, Braunwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [erratum apppears in N Engl J Med 2006;354(16):778]. N Engl J Med 2004;350(15):1495-1504.
22. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080.
23. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32(1):140-146.
24. Ridker PM, Cook NR, Lee IM, et al. A randomized trail of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304.
25. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332(26):1758-1766.
26. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-1297.
27. Yang X, Schadt EE, Wang S, et al. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res. 2006;16(8):995-1004.
28. Isensee J, Witt H, Pregla R, et al. Sexually dimorphic gene expression in the heart of mice and men. J Mol Med. 2008;86(1):61-74.
29. Heid IM, Jackson AU, Randall JC, et al. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet. 2010;42(11):949-960.
30. Hart EC, Charkoudian N, Wallin BG, et al. Sex differences in sympathetic neural-hemodynamic balance: implications for human blood pressure regulation. Hypertension. 2009;53(3):571-576.
31. Liu CC, Kuo TB, Yang CC. Effects of estrogen on gender-related autonomic differences in humans. Am J Physiol Heart Circ Physiol. 2003;285(5):H2188-H2193.
32. Duckles SP, Miller VM. Hormonal modulation of endothelial NO production. Pflugers Arch. 2010;459(6):841-851.
33. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA. 2004;291(24):2969-2977.
34. Pollak A, Rokach A, Blumenfeld A, et al. Association of oestrogen receptor alpha gene polymorphism with the angiographic extent of coronary artery disease. Eur Heart J. 2004;25(3):240-245.
35. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol Rev. 2008;60(2):210-241.
36. Miller VM, Jayachandran M, Owen WG. Aging, oestrogen, platelets and thrombotic risk. Clin Exp Pharmacol Physiol. 2007;34(8):814-821.
37. Kalantaridou SN, Naka KK, Bechlioulis A, et al. Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol Metab. 2006;17(3):101-109.
38. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008;14(3):111-116.
39. Shuster LT, Rhodes DJ, Gostout BS, et al. Premature menopause or early menopause: Long-term health consequences. Maturitas. 2010;65(2):161-166.
40. Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009;2(3):228-239.
41. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause. 2007;14(3 pt 1):373-384.
42. Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol. 2008;51(3):564-580.
43. Manson J, Allison M, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591-2602.
44. Canonico M, Oger E, Plu-Bureau G, et al; Estrogen and Thromoembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845.
45. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001;103(10):1410-1415.
46. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril. 1992;57(3):505-513.
47. Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf). 1999;50(4):517-527.
48. Paradisi G, Steinberg HO, Shepard MK, et al. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(2):576-580.
49. Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab. 2010;95(2):722-730.
50. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24(3):313-340.
51. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrinol Metab 2005;90(5):2708-2711.
52. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010; 363(2):109-122.
53. Santen RJ, Allred DC, Ardoin SP, et al; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95 (7 suppl 1):s1-s66.
54. Toh S, Hernández-Diaz S, Logan R, et al. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? Ann Intern Med. 2010;152(4):211-217.
55. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med. 2011;124(3):199-205.
56. Johnston JM, Colvin A, Johnson BD, et al. Comparison of SWAN and WISE menopausal status classification algorithms. J Womens Health (Larchmt). 2006;15(10):1184-1194.